Daily Brief Thematic (Sector/Industry): Anime-Related Stocks Become Hot Ticket Among Chinese Investors and more

In today’s briefing:

Anime-Related Stocks Become Hot Ticket Among Chinese Investors
APAC Healthcare Weekly (Dec 1)- Celltrion, Eoflow, Lunit, Hansoh, Kelun Biotech, Eisai, Dr. Reddy’s
Japan Weekly | T&D Soars on Higher Shareholder Returns

Anime-Related Stocks Become Hot Ticket Among Chinese Investors

China’s booming demand for physical products based on media intellectual property (IP) is increasingly reflected in the stock market, where related stocks have become a hot topic among investors.
These products, known in Chinese as “guzi” (谷子) — a transliteration of the English word “goods” — are based on IP from comics, anime, TV dramas and computer games.
Their prices vary widely.

Celltrion outlined mid- to long-term business outlook. European Patent Court has dismissed injunction against Eoflow. Lunit partnered with Salud Digna, one of Mexico’s largest healthcare chains.
China has accepted Hansoh Pharma’s fifth indication approval application for Ameile. Sichuan Kelun-Biotech received marketing authorization in China for the first domestically developed TROP2-directed ADC sacituzumab tirumotecan.
Eisai launched Leqembi in South Korea. Dr. Reddy’s launched new biologic drug, toripalimab in India, for the treatment of nasopharyngeal carcinoma. Aster DM is merging with Quality Care India Limited.

The Japanese stock market posted a muted performance this week, with the Nikkei 225 slipping 0.2% and the Topix declining 0.6%
The yen strengthened by 4.5 yen against the dollar, closing at its highest level in over two weeks
Sector-Wise, Textiles (+5%) led the market this week, with Wacoal (+8%), Goldwin (+4%) and Asics (+5%) all performing well.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network